Hopes that a vaccine to prevent HIV infection could finally be around the corner have been dashed after the failure of Johnson & Johnson's large-scale Phase IIb study in sub-Saharan Africa.
The primary analysis of the Imbokodo trial (also known as HVTN 705/HPX2008) in young women at risk of infection found...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
